Sugi Predict

Sugi Predict / Compounds / Bipenamol

Bipenamol

Bipenamol

SCHEMBL91233

NCc1ccccc1Sc1ccccc1CO

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ APOBEC3G Q9HC16 1/20 0.59
▸ SLC6A4 P31645 9/20 0.53
▸ SLC6A2 P23975 6/20 0.53
▸ SLC6A3 Q01959 3/20 0.53
▸ DPP4 P27487 1/20 0.42
▸ PNMT P11086 1/20 0.40
▸ LDHA P00338 1/20 0.40
▸ IFNAR1 P17181 1/20 0.39
▸ CYP2A6 P11509 1/20 0.38
▸ PRMT3 O60678 1/20 0.38
▸ CARM1 Q86X55 1/20 0.38
▸ PRMT6 Q96LA8 1/20 0.38
▸ PRMT8 Q9NR22 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bipenamol SCHEMBL29444593 1.00 APOBEC3G (0.59) APOBEC3GSLC6A4SLC6A2SLC6A3DPP4
Bipenamol SCHEMBL636892 0.98 APOBEC3G (0.57) APOBEC3GSLC6A4SLC6A2SLC6A3DPP4
Bipenamol SCHEMBL30791275 0.98 APOBEC3G (0.57) APOBEC3GSLC6A4SLC6A2SLC6A3DPP4
Bipenamol SCHEMBL28234193 0.91 APOBEC3G (0.50) APOBEC3GSLC6A4SLC6A2SLC6A3DPP4
SCHEMBL4442278 0.89 APOBEC3G (0.73) APOBEC3GSLC6A4SLC6A2SLC6A3LDHA
SCHEMBL27907181 0.89 SLC6A4 (0.61) APOBEC3GSLC6A4SLC6A2SLC6A3DPP4
SCHEMBL27794892 0.85 APOBEC3G (0.52) APOBEC3GSLC6A4SLC6A2SLC6A3DPP4
SCHEMBL5147860 0.84 APOBEC3G (0.55) APOBEC3GSLC6A4SLC6A2SLC6A3PRMT3
SCHEMBL9660814 0.83 SLC6A4 (0.68) APOBEC3GSLC6A4SLC6A2SLC6A3PNMT
SCHEMBL24018819 0.82 APOBEC3G (0.53) APOBEC3GSLC6A4SLC6A2SLC6A3IFNAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 637 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022159506-A1 DEUTERATED CANNABIDIOL COMPOUNDS MERIT THERAPEUTICS, INC. (US) 2022-07-28 — — WO claimed
WO-2022159507-A1 COMBINATION OF CANNABINOIDS WITH ADDITIONAL THERAPEUTIC AGENTS FOR TREATING DISEASES OR DISORDERS MERIT THERAPEUTICS, INC. (US) 2022-07-28 — — WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 — — US claimed
CN-102143961-B Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity NEURAXON INC 2014-11-05 — — CN claimed
US-8586620-B2 Substituted indole compounds having NOS inhibitory activity NEURAXON, INC. (CA) 2013-11-19 — — US claimed
JP-2011526251-A — — 2011-10-06 — — JP claimed
US-20110212947-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NEURAXON INC. (CA) 2011-09-01 — — US claimed
CN-102143961-A Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity NEURAXON INC 2011-08-03 — — CN claimed
CN-1665801-B Anti tubercular drug: compositions and methods DEPT OF HEALTH AND HUMAN SERVI 2011-05-11 — — CN claimed
EP-2310386-A1 BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY Neuraxon Inc. (CA) 2011-04-20 — — EP claimed
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. 2005-01-27 — — US claimed
US-20040242594-A1 Prodrugs of antidepressants and their use for treating depressions NEUROSEARCH A/S (DK) 2004-12-02 — — US claimed
WO-2004098589-A1 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES ELAN PHARMACEUTICALS, INC. (US) 2004-11-18 — — WO claimed
EP-1448512-A1 PRODRUGS OF ANTIDEPRESSANTS AND THEIR USE FOR TREATING DEPRESSIONS NeuroSearch A/S (DK) 2004-08-25 — — EP claimed
WO-2003042162-A1 PRODRUGS OF ANTIDEPRESSANTS AND THEIR USE FOR TREATING DEPRESSIONS NEUROSEARCH A/S (DK) 2003-05-22 — — WO claimed
US-6509393-B2 Phase change inks XEROX CORPORATION 2003-01-21 — — US claimed
US-20020137816-A1 Phase change inks XEROX CORPORATION 2002-09-26 — — US claimed
US-20020058788-A1 Facile deprotection of Fmoc protected amino groups DISCOVERY PARTNERS INTERNATIONAL, INC. 2002-05-16 — — US claimed
WO-1997041878-A1 TREATMENT OF MOOD DISORDERS WITH A GROWTH HORMONE SECRETAGOGUE MERCK & CO., INC. (US) 1997-11-13 — — WO claimed
US-4056632-A ANTIDEPRESSANT BURROUGHS WELLCOME CO. (US) 1977-11-01 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212947-A1 SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY NOS2, NOS1, NOS3 APOBEC3G 3863/4885SLC6A4 215/4885SLC6A2 920/4885
US-20050020659-A1 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists BDKRB1, BDKRB2, BRS3 APOBEC3G 4508/4885SLC6A4 2641/4885SLC6A2 2937/4885
US-20040242594-A1 Prodrugs of antidepressants and their use for treating depressions TPH1, SLC6A4, TPH2 APOBEC3G 925/4885SLC6A4 2/4885SLC6A2 4/4885
US-20020058788-A1 Facile deprotection of Fmoc protected amino groups DNPEP, LNPEP, NPEPPS APOBEC3G 387/4885SLC6A4 2007/4885SLC6A2 2283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.